Activation of the RAS pathway has been described as a mechanism of primary or secondary resistance in colon cancer, where the presence of KRAS activating mutations in the primary tumor is a negative predictive factor of response to the anti-EGFR monoclonal antibodies cetuximab and panitumumab [29, 30]. This evidence concerns the gene KRAS and colonic neoplasm.